InxMed Co., Ltd announces that clinical data of Ifebemtinib, a highly potent and selective oral inhibitor of focal adhesion kinase, in platinum-resistant recurrent ovarian cancer and triple-negative breast cancer has been presented at the 2023 European Society for Medical Oncology Congress taking place October 20-24 in Madrid, Spain.
